Trials / Completed
CompletedNCT03241745
A Study of Nivolumab in Selected Uterine Cancer Patients
Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.
Conditions
- Uterine Cancer
- Endometrial Carcinoma
- Carcinosarcoma
- Leiomyosarcoma
- Undifferentiated Sarcoma
- High Grade Endometrial Stromal Sarcoma
- Clear Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Nivolumab 480 mg IV once every 4 weeks |
Timeline
- Start date
- 2017-08-03
- Primary completion
- 2024-04-01
- Completion
- 2024-04-01
- First posted
- 2017-08-07
- Last updated
- 2024-12-27
- Results posted
- 2024-12-27
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03241745. Inclusion in this directory is not an endorsement.